Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 25% revenue increase, improved gross margin, and a shift from net loss to net income. Although operating expenses rose, they were due to strategic investments. The guidance for 2026 indicates continued growth, and cash flow improvements further reinforce a positive outlook. Despite inherent risks in forward-looking statements, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Key Financial Performance
Revenue Castle Biosciences reported a revenue of $50 million for Q1 2026, representing a 25% increase year-over-year. This growth was attributed to the successful launch of new diagnostic tests and an increase in test volume.
Gross Margin The gross margin for Q1 2026 was 75%, up from 70% in Q1 2025. The improvement was driven by operational efficiencies and cost reductions in test processing.
Net Income Net income for Q1 2026 was $5 million, compared to a net loss of $2 million in Q1 2025. This turnaround was due to higher revenues and better cost management.
Operating Expenses Operating expenses increased by 10% year-over-year to $30 million, primarily due to investments in research and development and marketing for new products.
Cash Flow Cash flow from operations was $10 million in Q1 2026, up from $6 million in Q1 2025. The increase was driven by improved profitability and efficient working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company made forward-looking statements about expected addressable markets and projections regarding future events or financial and operational results. These statements inherently carry risks as they are based on assumptions about future conditions, which may not materialize as expected.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Anticipated 2026 Total Revenue: Statements were made about the company's projections regarding future financial results and performance, specifically mentioning anticipated total revenue for 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Affairs Derek
Affairs statement
CFO Treasurer
Canaccord Genuity
Carrico Stephens
Catherine Ramsey
Derek Maetzold
Director Frank
Division Catherine
Division Flaten
Division Kyle
Division PM
Division Parisi
Division Puneet
EDT afternoon
Flaten Lake
Frank Stokes
Genuity Corp
Inc Research
Kyle Mikson
LLC Research
Markets Inc
Mikson Canaccord
PM EDT
Parisi KeyBanc
Partners LLC
Ramsey Baird
Research Division
Stephens Inc
Stokes CFO
Treasurer Mason
CSTL Transcript
Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with a 25% revenue increase, improved gross margin, and a shift from net loss to net income. Although operating expenses rose, they were due to strategic investments. The guidance for 2026 indicates continued growth, and cash flow improvements further reinforce a positive outlook. Despite inherent risks in forward-looking statements, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call highlights increased operating expenses and a net loss for 2025, contrasting with a previous net income. Adjusted EBITDA has significantly decreased, and there is uncertainty around FDA approval and NCCN guideline inclusion for key products. Despite strong market opportunities and revenue guidance, these financial concerns and vague management responses suggest a negative market reaction.
Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript
Unknown11-3
The earnings call presents mixed signals: positive revenue growth and pipeline developments are countered by declining margins, increased expenses, and a net loss. The raised revenue guidance is a positive sign, but the lack of clarity on reimbursement pathways and flat SCC volumes temper enthusiasm. The Q&A reveals some analyst concerns, particularly regarding reimbursement and FDA approval impacts. The absence of a market cap limits prediction accuracy, but the overall sentiment leans towards neutral, given the balancing of positive growth prospects against financial pressures and uncertainties.
Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript
Positive8-4
The earnings call summary and Q&A indicate positive sentiment, driven by raised revenue guidance, strong growth in TissueCypher and DecisionDx-Melanoma tests, and optimistic future cash flow expectations. Despite some uncertainties in FDA submission timelines and reimbursement pathways, the overall outlook is upbeat. The company's strategic initiatives and growth potential in the GI space further bolster confidence. The market is likely to react positively, with stock price expected to rise by 2% to 8% over the next two weeks.
CSTL Slides
CSTL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
